The H19 large intergenic non-coding RNA (lincRNA) is one of the most highly abundant and conserved transcripts in mammalian development, being expressed in both embryonic and extra-embryonic cell lineages, yet its physiological function is unknown. Here we show that miR-675, a microRNA (miRNA) embedded in H19 's first exon, is expressed exclusively in the placenta from the gestational time point when placental growth normally ceases, and placentas that lack H19 continue to grow. Overexpression of miR-675 in a range of embryonic and extra-embryonic cell lines results in their reduced proliferation; targets of the miRNA are upregulated in the H19 null placenta, including the growth-promoting insulin-like growth factor 1 receptor (Igf1r ) gene. Moreover, the excision of miR-675 from H19 is dynamically regulated by the stress-response RNA-binding protein HuR. These results suggest that H19 's main physiological role is in limiting growth of the placenta before birth, by regulated processing of miR-675. The controlled release of miR-675 from H19 may also allow rapid inhibition of cell proliferation in response to cellular stress or oncogenic signals.
One way by which lincRNAs may acquire functionality is by acting as the precursor to small RNAs capable of regulatory function, such as microRNAs (refs 9-11) . Indeed, exon 1 of H19 harbours a miRNA-containing hairpin that has been found to serve as the template for two distinct miRNAs, miR-675-5p and miR-675-3p (ref. 12) , and it has been suggested that it may be these miRNAs that confer functionality on H19 (refs 4,12,13; Fig. 1a) . Moreover, the miR-675 stem loop was shown to be one of the most highly conserved features of the H19 RNA during mammalian evolution, indicating that selective pressure may be higher on the miRNAs than on H19 as a whole 7 .
RESULTS

miR-675 is expressed in placenta but processing is strongly inhibited
To investigate the possibility that H19 derives its functionality from miR-675, we determined the expression profile of the miRNA. As H19 is the primary miRNA (pri-miRNA) template for miR-675, we examined its expression in tissues where H19 is highly transcribed. Unexpectedly, both species of miR-675 were barely detectable in fetal liver (endoderm-derived tissue) and fetal heart (mesoderm-derived tissue) at all stages of embryonic development tested, despite the vast levels of H19 (Fig. 1b,c) , suggesting that processing of the miRNA from H19 is inhibited. Indeed, large-scale miRNA profiling studies have also found only low levels of miR-675 in the embryo despite abundant H19 (refs 14,15) . Low levels of miR-675 were also identified in human cell lines 16 , implying that the inhibition of miR-675 processing is evolutionarily conserved. In contrast to fetal tissues however, we observed miR-675 to be expressed in the placenta exclusively from the maternal allele and with increasing abundance from E11.5 until term, despite there being no change in the abundance of H19 (Figs 1e and 3a and Supplementary Fig. S1a ). This suggests that not only is miR-675 processing inhibited but that this inhibition is a dynamic process that can be relaxed to allow expression of the miRNA. No miR-675 expression was detected in fetal brain, where H19 is absent (Fig. 1d) .
By comparison with a miRNA universal standard, which contains known concentrations of most miRNAs, the number of molecules of miR-675 per cell was found to be very low in embryonic tissue (approximately 40 copies in fetal heart and 70 in fetal liver), indicating that miR-675 is most likely non-functional in these tissues ( Fig. 1b-e) . When miR-675 reaches its peak of expression in the E19.5 placenta however, there are approximately 300 copies of miR-675-5p and 1,000 copies of miR-675-3p per placental cell. The previously characterized miRNA let-7 is known to be functional in HeLa cells at a similar concentration 17, 18 . Despite this potentially functional abundance, miR-675 levels are only 1% of H19 levels, demonstrating both the very high abundance of H19 and also an unusually tight inhibition of miRNA processing.
Relative RNA levels Relative RNA levels Microarray data from a published study of transcription during placental development 19 were reanalysed and the kinetics of HuR expression are shown from E8.5 until birth (P0). Note that HuR expression is inverse to that of miR-675 during placental development. Data are from at least two biological and two technical replicates. (c) RNA immunoprecipitation with an antibody against HuR indicates binding to H19 in the placenta at a gestational time point when miR-675 is suppressed (E11.5) but not when it is expressed (E19.5). The enrichment of RNA over a random IgG control is shown following normalization to the 18s RNA. Levels of Actb and Gapdh are included as positive and negative controls, respectively. n = 9. (d) RNA immunoprecipitation with an antibody against HuR indicates binding to H19 in MEF cells. The enrichment of RNA over a random IgG control is again shown following normalization to the 18s RNA. Levels of p21 and Gapdh are included as positive and negative controls, respectively. n = 11. (e) The expression of miR-675-5p, miR-675-3p or miR-16 in MEF cells following treatment with either an siRNA against HuR (si-HuR) or a non-targeting scrambled control (si-scrambled) as determined by qRT-PCR. n = 4. (f) The expression of miR-675-5p, miR-675-3p or miR-16 in MEF cells that genetically lack HuR (HuR −/− ). n = 5. (g) The expression of miR-675-5p, miR-675-3p or miR-16 in C2C12 cells following treatment with either an siRNA against HuR (si-HuR) or a non-targeting scrambled control (si-scrambled) as determined by qRT-PCR. n = 4. All error bars indicate the s.e.m. P values were determined by Student's t -test. * P < 0.05, * * P < 0.01, * * * P < 0.001. HuR has no effect on Dicer processing of pre-miR-675. n = 3. Statistical significance was determined by Student's t -test. * * P < 0.01, * * * P < 0.001. (d,e) H19 expression in nuclear and cytoplasmic cell fractions from both wild-type and HuR null (HuR −/− ) MEF cells, measured by qRT-PCR. To assess the quality of fractionation, the nuclear 45s transcript and the cytoplasmic 18s transcript were measured (d). H19 expression was measured in the different fractions (e). n = 6. (f-i) Nuclear and cytoplasmic fractionation of placental tissue was performed from different developmental time points. The quality of fractionation was assessed by measuring the 45s and 18s transcripts by qRT-PCR (f). H19 expression was measured in the input (g), cytoplasmic (h) and nuclear (i) fractions. n = 3. All error bars show the s.e.m. miR-675 processing is inhibited by the RNA-binding protein HuR As inhibition seems to be a dynamic process in the placenta, we reasoned that RNA-binding proteins might contribute to miR-675 regulation and hence performed RNA affinity assays followed by mass spectrometry to identify proteins that bind H19 in the region of the miR-675 stem loop (see Methods). We used partially differentiated trophoblast stem (TS) cell lysate as a cell culture approximation of early gestation placenta as these cells do not express miR-675 despite robust H19 levels ( Supplementary Fig. S1b,c) . Using this approach we identified 49 proteins that were bound selectively to H19 in the region of the miR-675 stem loop (Fig. 2a) . Notably, these included a number of proteins that are implicated in RNA metabolism and small RNA regulation, such as Upf1, Zcchc11, Luc7l and HuR. Amongst these, the RNA-binding protein HuR stood out as a candidate for regulating miR-675 processing, for a number of reasons: first, there is a putative HuR-binding site in H19 55 base pairs (bp) upstream from the miR-675 stem loop (AUUUUA), second, expression of HuR in the placenta declines during development as that of miR-675 increases 19 ( Fig. 2b) , and third, HuR is known to afford messenger RNAs protection from endonucleases (the miRNA-processing enzymes Drosha and Dicer are both RNAse III class endonucleases 20 ). Finally, knockout of HuR results in specific defects of the placenta 21 . We also found HuR expression to be higher in the liver, where miR-675 is silent, than it is in the late gestation placenta (data not shown).
We performed RNA immunoprecipitation with an antibody to HuR and found that it bound to full-length H19 in placenta at E11.5, when miR-675 is suppressed and HuR levels are high, but not at E19.5, when miR-675 is expressed and HuR levels are lower (Fig. 2c) . We sought to identify a cell culture model in which to perform functional studies. miR-675 is suppressed in primary mouse embryonic fibroblast (MEF) cells despite robust expression of H19 ( Supplementary Fig. S1d ), suggesting that inhibition of processing occurs in these cells; RNA immunoprecipitation experiments indeed confirmed HuR binding to H19 (Fig. 2d) . To assess the role of HuR in the suppression of miR-675 processing, we performed short interfering RNA (siRNA)-mediated knockdown in MEF cells and found that levels of both miR-675-5p and miR-675-3p were increased approximately 2-and 1.5-fold, respectively, in the absence of HuR (Fig. 2e and Supplementary Fig. S2a,b) . A similar effect was observed in MEF cells genetically deficient for HuR (HuR −/− ), where both miR-675-5p and miR-675-3p were increased by approximately 2-and 2.2-fold respectively relative to wild-type controls (Fig. 2f) . Finally, we ablated HuR in a myoblast cell line (C2C12) by siRNA knockdown and again found that miR-675-5p and miR-675-3p . P values were determined by Student's t -test. All error bars indicate the s.e.m. * P < 0.05, * * P < 0.01, * * * P < 0.001. levels were increased in the absence of HuR, by 2.8-and 3.5-fold, respectively ( Fig. 2g and Supplementary Fig. S2c,d ). In all cell culture models of HuR deficiency, levels of miR-16 were unchanged relative to controls, suggesting that the regulatory effect of HuR ablation is specific to miR-675 as opposed to the broader miRNA-processing pathway. Thus, HuR negatively regulates processing of both species of miR-675. Luc7l knockdown also resulted in increased miR-675 levels, suggesting that HuR is not the only negative regulator of processing ( Supplementary Fig. S2b ).
HuR does not block miR-675 processing at the Dicer step and probably blocks Drosha
We next sought to identify where in the miR-675-processing pathway HuR acts to inhibit processing. miRNAs are processed sequentially from longer hairpin-containing RNAs, first in the nucleus from the pri-miRNA by Drosha to create the pre-miRNA and second in the cytoplasm by Dicer to create the mature miRNA (ref. 22 ). The abundance of H19 (the pri-miRNA) suggests that processing of miR-675 is inhibited at the Drosha stage. To investigate this further, we performed northern blot experiments on fetal liver and placental RNA and found only low levels of pre-miR-675, the product of Drosha cleavage of H19 (Fig. 3a,b) . Moreover, when we transfected synthetic pre-miR-675 into MEF cells, we observed an increase in mature miR-675 and this increase was not altered by the presence or absence of HuR, showing that processing by Dicer was not affected by HuR (Fig. 3c) . Finally, our RNA immunoprecipitation experiments showed that HuR binds to the full-length H19 RNA (Fig. 2c,d ). Taken together these data suggest that HuR binds the full-length H19 RNA and inhibits processing of miR-675 at the Drosha step. Nevertheless, HuR ablation does not result in complete processing of H19, suggesting that other mechanisms exist to protect H19 from Drosha cleavage, possibly including the other H19 RNA-binding proteins we identified. Drosha localizes exclusively to the nucleus whereas the H19 RNA is known to localize predominantly to the cytoplasm 1,2 , and thus it is likely that HuR (and perhaps other RNA-binding proteins) protects H19 from processing by Drosha while it is localized to the nucleus, but that another level of protection is afforded by nuclear export of H19. A family of Igf2 mRNA-binding proteins have been implicated in the cytoplasmic localization of H19 (ref. 23 ) and these proteins are thus additional candidates for conferring inhibition of miR-675 processing. To determine whether HuR affects the nuclear export of H19, we performed nuclear and cytoplasmic RNA fractionations from wild-type and HuR −/− MEF cells and found no change in the abundance of nuclear H19 (Fig. 3d,e) . Moreover, fractionation of placental RNA revealed that the increasing miR-675 expression observed in that organ is not due to increased nuclear H19 levels ( Fig. 3f-i) .
miR-675 slows cell proliferation
The fact that miR-675 has been conserved during evolution, despite suppression of its processing, suggests a function for the miRNA as well as a need for precise regulation of its dosage. To examine its function we transiently transfected miR-675-5p and miR-675-3p mimics into MEF, C2C12, TS and ES cell lines and found that the proliferation rate of all cell lines was reduced by at least 50% in the presence of miR-675 when compared with a scrambled control (Fig. 4a-d) .
TdT-mediated dUTP nick end labelling (TUNEL) staining showed ∆3 placenta imply that miR-675 is a negative growth regulator in this tissue. (a) Placental weight was measured for homozygous H19 ∆3 crosses and compared with the wild type, revealing an overgrowth phenotype for the knockout that is more severe in the placenta than the embryo. The number of placentas measured for each data point is indicated above each bar. Error bars indicate the s.e.m. P values were determined by Student's t -test. * * * P < 0.001. (b) Representation based on real data showing the correlation of mir-675 (blue) and HuR (ref. 19 ; orange) expression in the placenta with the developmental weight of that organ (black). The weight of the H19 ∆3 placenta is also indicated (dashed line). At E13.5 there is a rapid drop in HuR expression concomitant with the induction of miR-675. At approximately E15.5, the wild-type placenta ceases to increase in mass 25 ; however, this does not occur in the H19 that this effect was not due to increased apoptosis ( Supplementary Fig.  S3a ), rather we noticed that the negative regulator of cell cycle Rb1 was upregulated by miR-675, indicating a possible reduction of cell cycle rate (Supplementary Fig. S3b ). Interestingly, it was not a single species of miR-675 that was responsible for the reduced proliferation, but rather miR-675-5p slowed the rate of proliferation of ES, TS and to a lesser extent MEF cells, whereas miR-675-3p slowed that of MEF and C2C12 cells. To confirm these results we used the A2lox.cre ES cell line 24 to create cells capable of doxycycline-induced expression of either miR-675-5p (A2lox-5p), miR-675-3p (A2lox-3p) or a scrambled control (A2lox-scrambled). To avoid inhibition of processing we placed these miRNAs in the miR-30 hairpin context and observed selective upregulation of either species of miR-675 on the addition of doxycycline (Supplementary Fig. S4 ). Cell proliferation assays confirmed the results of the transient miR-675 mimic experiments in ES cells, in that proliferation of the A2lox-5p cell line was slowed by the addition of doxycycline, whereas no effect was observed on the A2lox-3p or A2lox-scrambled cell lines (Fig. 4e-g) .
H19 was first shown to have tumour-suppressor properties by overexpression in the G401 metastatic rhabdoid tumour cell line 5 . We investigated whether miR-675, rather than H19 itself, may have been responsible for this previously reported effect by overexpressing the smaller RNA in these cells. Indeed, we observed reduced proliferation of G401 cells when treated with miR-675-5p as opposed to a scrambled control (Fig. 4h) . Finally, we took advantage of the fact that both H19 and miR-675 become expressed in differentiating C2C12 cells (Supplementary Fig. S5 ) to perform antagomiR-mediated loss-of-function experiments and found that proliferation of these cells increased when miR-675-3p was inhibited (Fig. 4i) . Taken together these results show that miR-675 is a functional component of the H19 RNA, capable of suppressing cell proliferation.
Deletion of both H19 and miR-675 results in placental overgrowth
Given the growth-limiting effect of miR-675, it was interesting to note that expression of the miRNA in the placenta is concomitant with the natural cessation of the growth of that organ 25 . Moreover, mice that carry a 13-kb deletion that includes H19, miR-675 and 10 kb of regulatory sequences upstream of H19 show an overgrowth phenotype that is more severe in the placenta (145% wild-type) than the embryo [26] [27] [28] (123% wild type). The interpretation of this phenotype, however, is complicated by the fact that the deletion (of the imprinting control region upstream of H19) also results in overexpression of the linked Igf2 gene 29 . To examine the possibility that the H19 RNA itself regulates placental growth, we studied an alternative H19 mouse model (H19 ∆3 ) that carries a 3-kb deletion of just the H19 transcription unit, including miR-675 (ref. 30 ). This deletion specifically ablates the H19 RNA without affecting expression of Igf2 in the placenta 8 ( Supplementary Fig. S6a ). Notably, placentas carrying the H19 ∆3 allele were 32% larger than wild types at E18.5, whereas the mutant embryos themselves were only 8% larger than wild type, in agreement with previous results 30 ( Fig. 5a and Supplementary Fig. S6c ). Expression of miR-675 in the placenta correlates with a rapid drop in the expression of HuR and the natural cessation of placental growth, which does not occur in the absence of H19 and miR-675 (Fig. 5b) , implying that miR-675 is a negative regulator of placental size. ∆3 placentas at either E11.5 or E18.5. Endogenous miR-675 expression in the placenta is indicated by the shaded triangle. n = 4. All error bars indicate the s.e.m. P values were determined by Student's t -test. * P < 0.05, * * * P < 0.001.
The H19
∆3 placental transcriptome reveals targets of miR-675 miR-675 is expressed most highly in the labyrinthine zone of the placenta when compared with the junctional zone ( Supplementary  Fig. S7a-d) ; to determine the effect of miR-675 on the H19 ∆3 transcriptome, we performed RNA sequencing on RNA from the labyrinthine zone in the E18.5 H19 ∆3 placenta. We found 285 genes upregulated and 59 downregulated by greater than twofold in the mutant versus the control labyrinth ( Supplementary Fig. S7e ). Gene ontology categories enriched in the H19 ∆3 transcriptome were consistent with growth and morphogenesis of the placenta (Fig. 5c ). H19 has previously been reported to regulate a network of imprinted genes in fetal muscle but not placenta 8 . Indeed, we observed no specific deregulation of imprinted genes in the H19 ∆3 placenta. We found computationally predicted targets of miR-675 enriched in the genes upregulated in the H19 ∆3 placenta (P = 0.0254). We co-transfected miR-675-5p and miR-675-3p mimics into ES, C2C12 and MEF cells and monitored the effect on 35 predicted targets by quantitative PCR with reverse transcription (qRT-PCR; Fig. 6a-c) , many of which (45%) were found to be downregulated by miR-675. However, genes that seemed to be targets in one cell line were not necessarily targets in another. This suggests that the target network by which miR-675 slows cell proliferation is of a complex nature and may be distinct in different cell types.
Igf1r is a potential target of miR-675
Among the targets validated in cell lines, Igf1r was of particular interest because it is the key receptor through which Igf2 exerts its growth-promoting effect during fetal development. Igf1r is a predicted target of miR-675-3p and contains two 7-mer seed matches in its 3 UTR (Fig. 6d) . We cloned the Igf1r 3 UTR downstream of a luciferase reporter construct and co-transfected it into cells alongside either a miR-675-3p mimic or a scrambled control. We found that luciferase levels were reduced by more than 60% in the presence of miR-675-3p (Fig. 6e ). This effect was not observed when the miR-675-3p-binding sites were mutated; thus, Igf1r is a potential target of miR-675-3p. Moreover, Igf1r was found to be upregulated in H19 ∆3 placentas only at the time when miR-675 is expressed (E18.5) and not when it is silent (E11.5; Fig. 6f ), suggesting that it is a target of the microRNA in vivo.
DISCUSSION
Our results suggest that a physiological role of H19 is to slow down growth of the placenta in the second half of gestation, in preparation for parturition. This seems to be achieved at least in part by downregulation of the RNA-binding protein HuR during gestation, which normally blocks processing of miR-675 at the Drosha stage. Increased levels of miR-675 in the placenta are concomitant with downregulation of Igf1r, amongst other targets that may also contribute to reduced growth. Igf1r has been shown to be an important regulator of growth 31, 32 , with its main ligand during development being Igf2. Remarkably, the H19 locus therefore regulates the abundance of Igf2 (through imprinting) and that of its receptor, Igf1r, through miR-675.
Although data presented here apply to growth regulation in the placenta under physiological conditions, it is notable that in embryonic tissues miR-675 remains tightly repressed despite the high levels of H19. We speculate that the enormous reservoir of the growth-suppressing miR-675 could be rapidly mobilized in response to cellular stress or abnormal proliferation. Indeed, HuR is known to relocate from the nucleus to the cytoplasm in stress conditions [33] [34] [35] [36] and on pharmacologically induced neoplastic transformation 37 . This would expose H19 to processing by Drosha, thus liberating miR-675. HuR was recently shown to suppress processing of human miR-7 from the highly expressed HNRNPK transcript 38 . That miR-7 is also a known tumour suppressor [39] [40] [41] that functions partly through Igf1r targeting 41 may suggest a wider miRNA repertoire for a HuR-mediated response to aberrant cell proliferation. The H19 RNA being a regulatable reservoir of the proliferation-suppressing miR-675 may thus explain the lincRNAs tumour-suppressive role, especially in childhood tumours 42 . The mechanisms of processing and function of miR-675 are likely to be relevant to the molecular pathology of fetal growth and cancer syndromes.
METHODS
Methods and any associated references are available in the online version of the paper at www.nature.com/naturecellbiology 
Cell culture. ES cells were the J1 line and were maintained on gelatinized dishes in ES media (Dulbecco's modified Eagle's medium (DMEM) containing sodium pyruvate and l-glutamine, supplemented with 15% fetal bovine serum (Invitrogen), 1% penicillin/streptomycin, 1× non-essential amino acids, 0.05 mM 2-mercaptoethanol and leukaemia inhibitory factor (LIF; 1,000 units ml −1 ; Millipore)).
TS cells were the TS-rs26 line derived in the Rossant Laboratory, cultured in standard conditions (RPMI 1640 supplemented with 20% fetal bovine serum (Invitrogen), 1% antibiotic/antimycotic solution, 1× sodium pyruvate and 0.05 mM 2-mercaptoethanol, 20 ng ml −1 b-fetal growth factor (bFGF; Sigma) and 1 µg ml −1 heparin (Sigma) with 70% of the media preconditioned with embryonic feeder cells 43 ). Differentiation was achieved by culturing without bFGF or heparin in unconditioned media.
C2C12 cells were cultured in growth media (DMEM) supplemented with 200 mM l-glutamine and 10% fetal bovine serum (PA)). Differentiation was induced by culturing in differentiation media (DMEM supplemented with 200 mM l-glutamine and 2% horse serum (Invitrogen)).
MEF cells were derived from C57/BL6J x CBA mice and cultured in ES cell media without LIF. HuR −/− MEFs have been previously described 21 . RNA was isolated from cells using the Qiazol method (Qiagen).
Animal studies. Mice used for the expression studies were the C57/BL6 strain.
The H19
∆3 transgenic line has been previously described 30 . All experiments were performed under Home Office licence and in accordance with the Animals (Scientific Procedures) Act of 1986. To define developmental stage, the day of conception is considered to be day 0.5 of pregnancy.
RNA was isolated from animal tissue using the Qiazol method (Qiagen).
Generation of A2lox-miR-675 cell lines.
Hairpins containing the microRNA required for expression, miR-30 flanking sequences and overhangs matching the restriction site fragments, XhoI and EcoRI, were annealed to their corresponding complementary oligomer (Supplementary Table S1 ) and cloned into the PSM2 vector (Open Biosystems) using the restriction site overhangs. Constructs were PCR amplified using primers containing artificial NotI and HindIII restriction sites (5 -ATCAAGCTTCAGGGTAATTGTTTGAATGAGGC-3 and 5 -AGCGGCCGCGTCTTCCAATTGAAAAAAGTGA-3 ) and cloned into the p2lox vector followed by transfection into the A2lox.cre ES cell line 24 . The day before transfection, Cre was induced by the addition of doxycycline (0. 5 µg ml −1 ). Cells were transfected with 2 µg of p2lox plasmid using Lipofectamine 2000 (Invitrogen) and selection for stable integration with geneticin (300 µg ml −1 , Melford) for 10 days. Single colonies were picked and expanded. Expression of hairpin constructs was achieved by the addition of doxycycline (2 µg ml −1 ) to the ES media.
RNAi knockdown. RNAi-mediated knockdown of mRNAs was achieved in all cell types by Stealth RNAi oligos (Invitrogen) against HuR (Catalogue no. mss205313), Serbp1 (Catalogue no. mss288826), Upf1 (Catalogue no. mss208598), Zcchc11 (Catalogue no. mss279478), Ptbp2 (Catalogue no. mss225938), Luc7l (Catalogue no. mss250251) or a non-targeting control (Catalogue no. 12935-300), at a final concentration of 50 pmol ml −1 . Transfection of RNAi oligos into cell lines was achieved using Lipofectamine 2000 (Invitrogen). RNA was extracted 48 h later.
Cell proliferation assays. Pre-miR miRNA precursor molecules for miR-675-5p, miR-675-3p, has-miR-1 or Negative Control #1 (Ambion) were transfected into all cell lines at a final concentration of 24 nM using Lipofectamine 2000 (Invitrogen). Cells were collected using trypsin (0.05%) and then counted using a Nikon TMS microscope and a haemacytometer (Assistent).
C2C12 cells maintained in growth media (described above) were transfected with either antagomiR molecules against miR-675-3p or a scrambled control (Invitrogen) to a final concentration of 30 nM using Lipofectamine 2000 (Invitrogen) for 6 h, before inducing differentiation by the addition of differentiation media (described above). Cells were maintained in differentiation media for 2 days before a second round of antagomiR transfection. Cells were maintained for a further 3 days before being collected with trypsin (0.05%) and counted using a Nikon TMS microscope and a haemacytometer (Assistent).
Quantitative PCR. qRT-PCR was performed using primers from Supplementary   Table S2 .
MicroRNA qRT-PCR was performed with TaqMan MicroRNA assays (Applied Biosystems) and normalized to the U6 RNA according to the manufacturers guidelines. For absolute quantification of miRNA levels, threshold cycle (Ct) values were compared to the Ct values of a standard curve produced by serial dilution and Taqman MicroRNA amplification of the miRXplore Universal Reference (MiltenyiBiotec).
For absolute quantification of H19 levels, part of H19 was amplified using the H19 reverse transcription primers (see Supplementary Table S2 ) and cloned into the pGEM T-easy vector (Promega). Standard curves were created by qRT-PCR using a dilution series of this vector that was used to measure absolute H19 levels in tissue samples.
Northern blotting.
To detect pre-miR-675, probes were PCR amplified from H19-containing plasmid DNA using a forward (5 -TGCGGCCCAGGGACTGGT-3 ) and reverse primer harbouring the T7 promoter (5 -GGATCCTAATACGACTCACTA-TAGGGAGAGGAGCCAGACCCAGGGACTGA-3 ). PCR products were reverse transcribed and radioactively labelled using [α-
32 P] rUTP. Total RNA was separated on a 15% TBE-Urea denaturing gel (Invitrogen). RNA was transferred to a GeneScreen Plus Hybridization Transfer membrane (Perkin Elmer) and incubated with labelled probe or labelled U6 RNA oligonucleotide (5 -TTGCGTGTCATCCTTGCGCAGG-3 ) for approximately 16 h. Membranes were exposed to X-ray film (Fujifilm).
For detection of mature miR-675, total RNA was separated on a 15% TBEUrea denaturing gel (Invitrogen). RNA was transferred to a GeneScreen Plus Hybridization Transfer membrane (Perkin Elmer) and ultraviolet crosslinked. Probes specific to miR-675-3p (Exiqon) or U6 RNA were labelled with ATP[γ - mRNA library preparation (RNA sequencing). RNA sequencing libraries were created, sequenced and mapped using an in-house protocol that has already been described 44 . Mapped sequence reads were analysed with the aid of the SeqMonk Mapped Sequence Analysis Tool (http://www.bioinformatics.bbsrc.ac.uk/projects/ seqmonk/). These data are available on the ArrayExpress database (http://www. ebi.ac.uk/arrayexpress/) with accession number E-MTAB-895. Sequencing data for miR-675 can be found on the miRBase database (http://www.mirbase.org/) with accession number MI0004123.
RNA affinity assay. Bait regions were PCR amplified from genomic DNA using appropriate primers (miR-675 stem: 5 -AATGGAAAAGAAGGGCAGTG-3 and 5 -CCCAGCTACTCGCTCTACCT-3 , 5 H19: 5 -AGACCTGGGCAGTGAAGGTA-3 and 5 -GCCACTGTCTCCAAGGACTC-3 , and Kcnq1ot1: 5 -TGGGTGGCCTCT-AATACTGG-3 and 5 -CTGCCCCTTCTCTATTGCAG-3 ) to produce amplicons of 343, 363 and 411 bp respectively. Note that the miR-675 stem fragment includes the putative HuR-binding site adjacent to the miR-675 stem loop. PCR products were cloned into the pGEM T-easy vector (Promega) and digested with ScaI (New England Biolabs) to define the 3 end before in vitro transcription. RNA-binding proteins were then isolated using previously described methods 45 . Proteins were identified by mass spectrometry. Briefly, Coomassie-stained gel lanes were excised, destained, reduced, carbamidomethylated and digested overnight with 10 ng ml −1 modified trypsin (Promega) in 25 mM ammonium bicarbonate at 30 • C. The resulting peptide mixtures were separated by reverse-phase liquid chromatography (column: 0.05 × 100 mm, Vydac C18, 5 mm particle size), with an acetonitrile gradient (5-40% over 30 min) containing 0.1% formic acid, at a flow rate of 150 nl min −1 . The column was coupled to a nanospray ion source (Protana Engineering) fitted to a quadrupole-time-of-flight mass spectrometer (Qstar Pulsar i; Applied Biosystems/MDS Sciex), operating in information-dependent acquisition mode.
RNA immunoprecipitation.
Cell lysate was produced from either cultured MEF cells or mechanically homogenized whole placentas by incubation in lysis buffer (100 mM KCl, 5 mM MgCl 2 , 10 mM HEPES, at pH 7, 0.5% NP-40 and 1× Complete mini Protease Inhibitor Cocktail tablets (Roche)). RNA immunoprecipitation was performed using 4 µg of antibody against HuR (3A2, Santa Cruz) or non-specific mouse IgG (Santa Cruz) and a previously described method 46 .
Luciferase assay. The miR-675 target sites within the Igf1r were PCR amplified using primers containing artificial XhoI and NotI restriction sites and cloned into the Psicheck2 vector (Promega) directly downstream of a luciferase reporter gene. miRNA-binding sites were mutated by PCR amplifying the Psicheck2-Igf1r vector with primers containing the required point mutations followed by removal of un-mutated plasmid by DpnI digestion. Plasmids (200 µg) were co-transfected into ES cells with miR-675 mimic (24 nM, Ambion) and the luciferase activity measured 24 h later using the Dual Glo luciferase assay (Promega).
TUNEL staining. Cells were treated with Pre-miR miRNA precursor molecules (Ambion), as described above, and maintained for 48 h before being collected and cytospun onto poly-l-lysine-coated slides. Apoptotic cells were detected using the DeadEnd Fluorometric TUNEL system (Promega 
